Global Antiretroviral Therapy Market 2017-2021
About Antiretroviral Therapy
The antiretroviral therapy (ART) market is primarily related to the treatment of human immunodeficiency virus (HIV) infection. Antiretroviral drugs are usually taken in combination to prevent the growth of the virus, which slows the growth of HIV infection. The major drivers for the ART market include the rising awareness of retroviral infection, aggressive innovation in diagnostic techniques, the introduction of novel drugs through significant investments made in R&D, and high unmet needs in the retrovirus infection treatment domain.
Technavio’s analysts forecast the global antiretroviral therapy market to grow at a CAGR of 2.64% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global antiretroviral therapy market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Antiretroviral Therapy Market 2017-2021
Technavio recognizes the following companies as the key players in the global antiretroviral therapy market: Gilead, ViiV Healthcare, Janssen Pharmaceuticals, and F. Hoffmann-La Roche
Other Prominent Vendors in the market are: Abbvie, Boehringer Ingelheim, Bionor Pharma, Vertex Pharmaceuticals, and Mylan
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Significant pipeline. Several promising antiretroviral agents are in the pipeline, which will boost the market growth in the long run. The approval of new therapeutic agents will broaden the options available for treatment and thus will lead to the increase in demand for therapeutic regimens. There are approximately 37 molecules under different clinical trial stages globally of which 18 molecules are in phase-II, and 13 molecules are in phase-III for various retroviral malignancies. The remaining molecules are in phase-I of their clinical trials.”
According to the report, one of the major drivers for this market is Rising awareness of retroviral infection. The awareness about retroviral infection is on the rise. Initiatives such as the Centers for Disease Control and Prevention's (CDC's) Act Against AIDS, targeted to make the youth aware of the risk of HIV infection because of concurrent use of alcohol and drugs, will drive the growth of the market. The initiatives by various governments also help to create awareness.
Further, the report states that one of the major factors hindering the growth of this market is High cost of antiretroviral drugs. High cost of treatment is one of the major challenges impeding the growth of the global ART market. The majority of patients in low and middle-income countries infected with HIV-1 and diagnosed after confirmatory tests fail to complete the course of treatment due to affordability concerns. According to the NIH, ART's success depends on patient adherence to the therapy course. Patients who had adhered 95% or above have shown a decrease in the viral load; the HIV RNA level was also non-detectable. Hence, the market can only experience growth if demand is high, which can only be possible if individuals are able to afford the cost of treatment. Therefore, it is essential to bring down the cost of drugs and treatment so that drug adherence, as well as adoption rate, improves.
Gilead, ViiV Healthcare, Janssen Pharmaceuticals, F. Hoffmann-La Roche, Abbvie, Boehringer Ingelheim, Bionor Pharma, Vertex Pharmaceuticals, and Mylan